Publication
Article
The State of Affairs of Osteoporosis Care: The Economic Implications of Current Practice
This supplement to The American Journal of Managed Care describes the impact of osteoporosis on healthcare and its current implications for managed care. It covers strategies that can be implemented to improve the diagnosis and management of osteoporosis along with new approaches to improve patient compliance and adherence with osteoporosis therapy.
FacultyDavid W. Dempster, PhD
Professor of Clinical Pathology
Columbia University
New York, New York
Jeffrey P. Levine, MD, MPH
Professor/Master Educators’ Guild
Director, Women’s Health Programs
Department of Family Medicine and Community Health
UMDNJ—Robert Wood Johnson Medical School
New Brunswick, New Jersey
Gary Owens, MD
President, Gary Owens Associates
Medical Management and Pharmaceutical Consultant
Glen Mills, Pennsylvania
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
David W. Dempster, PhD
Consultant/Advisory Board: Amgen, Eli Lilly, Merck
Grants: Eli Lilly
Speakers’ Bureau: Amgen, Eli Lilly
Jeffrey P. Levine, MD, MPH
Advisory Board: Amgen
Consultant: Bayer
Speakers’ Bureau: Merck
Gary Owens, MD
Advisory Board: Alimera Sciences, Amgen, Centocor Ortho Biotech, Eli Lilly, Genzyme, Johnson & Johnson, Novartis, Teva
Consultant: Allergan, Auxilium, Eyetech, GlaxoSmithKline, Genzyme, Pfizer
Board Member: Arthritis Foundation—Northeast Region
The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose.
Acknowledgement
Editorial support for this supplement was provided by Reshma Carter, PharmD; she has disclosed a spouse with a financial relationship with Bristol-Myers Squibb.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
The State of Affairs of Osteoporosis Care: The Economic Implications of Current Practice
Release date: May 15, 2011
Expiration date: May 15, 2012
Estimated time to complete activity: 2.5 hours
This activity is supported by an educational donation provided by Amgen.
Intended Audience
The audience for this supplement consists of medical directors, pharmacy directors, and other managed care professionals who oversee the care of patients with osteoporosis.
Statement of Educational Need
Considering the high prevalence and burden associated with osteoporosis, and the fact that it has been estimated that by 2050 the number of people over 65 years of age will increase from 32 million to 69 million, it is imperative that awareness, prevention, and treatment of postmenopausal osteoporosis improve. Managed care organizations (MCOs) are in a position to help improve osteoporosis care by implementing education and initiatives aimed at their patients and providers on various aspects of care, ie, adherence to guidelines, improved screening, improved follow-up care, and increased medication adherence. These tactics can help them improve outcomes and contain costs attributable to osteoporosis. Therefore, an educational activity geared toward managed care professionals on challenges and opportunities in osteoporosis care can help bridge the gaps and improve outcomes.
Educational Objectives
After completing this activity, the participant should be able to:
Disclosure Policy
According to the disclosure policies of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Physician Credit
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the University of Cincinnati. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Cincinnati designates this enduring material activity for a maximum of 2.5 AMA PRA Category 2.5 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacist Credit
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.5 contact hours (0.25 CEU) under the ACPE universal program number 0290-9999-11-033-H01-P. The program is available for CE credit through May 15, 2012.
Type of activity: Knowledge-based